Breakthrough in triple negative breast cancer shows optimal timing for immunotherapy

Abstract presented at the European Breast Cancer Conference:

“The ALEXANDRA/IMpassion030 trial is the first study to look at the role of chemotherapy with or without atezolizumab post-surgery for early-stage triple-negative breast cancer.” – Dr. McArthur

Interviews with study author and breast cancer expert Heather McArthur, M.D. now available.

Please email for interviews, thank you.